Document Detail

Are drug-eluting stents the preferred treatment for multivessel coronary artery disease?
MedLine Citation:
PMID:  16386659     Owner:  NLM     Status:  MEDLINE    
Drug-eluting stents (DES) constitute a major breakthrough in restenosis prevention after initial percutaneous coronary intervention (PCI). Target lesion and vessel revascularization rates of <10% at six months follow-up represent a significant medical advance. Many cardiologists consider it reasonable to assume that PCI using DES ought to be considered equivalent, if not superior, to bypass surgery. The argument made is that in previous randomized clinical trials comparing PCI to coronary artery bypass grafting, restenosis was the determining factor favoring surgery, an event that clinical experience suggests is no longer as frequent. In the absence of a definitive clinical trial to support this view, how should the prudent, cutting edge cardiologist evaluate the data and manage their patients?
Lloyd W Klein
Related Documents :
22937299 - Feminizing adrenal carcinoma presenting with heart failure and ventricular tachycardia.
24838039 - Interplay between arterial stiffness and diastolic function: a marker of ventricular-va...
23568589 - High-sensitivity cardiac troponin t levels and secondary events in outpatients with cor...
24839449 - G protein-coupled receptor kinase 2 as a therapeutic target for heart failure.
24816179 - Echocardiography and cardiac mri in mutation-negative hypertrophic cardiomyopathy in an...
23488909 - Second heart field and the development of the outflow tract in human embryonic heart.
24141839 - Right ventricular involvement in anterior myocardial infarction: a tissue doppler-deriv...
7151029 - Respiratory arrest and cervical spinal cord infarction following lumbar puncture in men...
23818649 - Right ventricular hypertrophy and failure abolish cardioprotection by ischaemic pre-con...
Publication Detail:
Type:  Comment; Journal Article     Date:  2005-12-13
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  47     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-01-02     Completed Date:  2006-03-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  22-6     Citation Subset:  AIM; IM    
Rush Medical College, Chicago, Illinois, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary*
Coronary Artery Bypass*
Coronary Disease / pathology,  surgery,  therapy*
Coronary Restenosis / prevention & control*
Paclitaxel / administration & dosage*
Sirolimus / administration & dosage*
Reg. No./Substance:
33069-62-4/Paclitaxel; 53123-88-9/Sirolimus
Comment On:
J Am Coll Cardiol. 2006 Jan 3;47(1):205-7   [PMID:  16386687 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Genomics and cardiac arrhythmias.
Next Document:  Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the...